Hyperglycemia results in decreased immune cell infiltration and increased viral load in the lung in a mouse model of RSV infection

Cytokine ◽  
2021 ◽  
pp. 155539
Author(s):  
Farshad Khodakhah ◽  
Alireza Tahamtan ◽  
Mona Marzban ◽  
Azadeh Shadab ◽  
Masoumeh Tavakoli-Yaraki ◽  
...  
Keyword(s):  
Viral Load ◽  
Mouse Model ◽  
Immune Cell ◽  
Cell Infiltration ◽  
Immune Cell Infiltration ◽  
Rsv Infection

Effects of ASCL1 expression on tumorigenesis and immune cell infiltration in a syngenic mouse model of lung adenocarcinoma

2019 ◽  
Author(s):  
Naoya Miyashita ◽  
Masafumi Horie ◽  
Yu Mikami ◽  
Hirokazu Urushiyama ◽  
Kensuke Fukuda ◽  
...  
Keyword(s):  
Mouse Model ◽  
Lung Adenocarcinoma ◽  
Immune Cell ◽  
Cell Infiltration ◽  
Immune Cell Infiltration

Construction of Hyaluronic Acid-CeO2 Conjugated Composite Nanoparticles and Their Activity Efficiency in Diabetic Retinopathy Alleviation

2021 ◽  
Vol 17 (11) ◽  
pp. 2219-2225
Author(s):  
Jingzhi Shao ◽  
Jingjing Wan ◽  
Fengyan Zhang ◽  
Lirong Zhang
Keyword(s):  
Diabetic Retinopathy ◽  
Hyaluronic Acid ◽  
Mouse Model ◽  
Clinical Efficacy ◽  
Structural Integrity ◽  
Foreign Body Reaction ◽  
Immune Cell ◽  
Cell Infiltration ◽  
Immune Cell Infiltration ◽  
Retinal Structure

We developed an effective nanoparticle-biomaterial in alleviating diabetic retinopathy (DR), hyaluronic acid (HA)-CeO2, composed mainly of CeO2 and HA. To demonstrate its anti-DR capacity, retinal cells from a B6/J mouse model were used to compare the efficiency of PEI-CeO2 and HA-CeO2. We investigated the transport performance, histolysis, immune cell infiltration, angiogenesis, and hyperemia induced by the transport system. The structural integrity, microvascular apoptosis, and superoxide and peroxide concentrations in the retina were measured to evaluate the clinical efficacy of CeO2. The infiltration efficiency of HA-CeO2 was higher than that of PEI-CeO2. Lower levels of foreign body reaction were evident for HA-CeO2 with less histolysis, immune cell infiltration, angiogenesis, and hyperemia. The clinical efficacy of HA-CeO2 in terms of preservation of retinal structure and lowering of microvascular apoptosis and superoxide and peroxide concentrations was superior to those of PEI-CP. HA-CeO2 was shown to have significant antioxidation and anti-vascular injury capacity in a mouse model, and may be a potential compound nanodrug for DR treatment in the future.

scholarly journals Selective In Vivo Visualization of Immune-Cell Infiltration in a Mouse Model of Autoimmune Myocarditis by Fluorine-19 Cardiac Magnetic Resonance

2013 ◽  
Vol 6 (2) ◽  
pp. 277-284 ◽  
Author(s):  
Ruud B. van Heeswijk ◽  
Jonathan De Blois ◽  
Gabriela Kania ◽  
Christine Gonzales ◽  
Przemyslaw Blyszczuk ◽  
...  
Keyword(s):  
Cardiac Magnetic Resonance ◽  
Magnetic Resonance ◽  
Mouse Model ◽  
Immune Cell ◽  
Cell Infiltration ◽  
Immune Cell Infiltration ◽  
Autoimmune Myocarditis

Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC).

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 270-270
Author(s):  
Austin G. Duffy ◽  
Oxana V. Makarova-Rusher ◽  
Drew Pratt ◽  
David E Kleiner ◽  
Suzanne Fioravanti ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Viral Load ◽  
Radiofrequency Ablation ◽  
Immune Cell ◽  
Human Monoclonal Antibody ◽  
Cell Infiltration ◽  
Immune Cell Infiltration ◽  
Advanced Hcc ◽  
Tumor Biopsies ◽  
Arterial Chemoembolization

270 Background: Tremelimumab is a fully human monoclonal antibody that binds to CTLA-4 expressed on the surface of activated T lymphocytes and results in inhibition of B7-CTLA-4-mediated downregulation of T-cell activation. Transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) and cryoablation (CA) have been shown to induce a peripheral immune response which may enhance the effect of anti-CTLA4 treatment in patients with advanced HCC. Methods: Patients with HCC [Childs Pugh A/B7; BCLC B/C; ECOG 0/1; post-sorafenib (BCLC stage C only)] or refractory BTC were enrolled in a study of Tremelimumab combined with subtotal TACE, RFA or CA performed on week 6. All BTC patients received RFA as the immune-stimulant in combination with tremelimumab. Tumor biopsies were performed at baseline and at time of RF/TACE. Results: 34 pts enrolled (28 HCC, 6 BTC). Characteristics: M:F 26:8; Median age 54(range 42-76); In HCC pts cirrhosis present in 17pts, BCLC Stage B/C: 9/19; Hepatitis B/C/neg: 4/15/9. 13 pts received TACE, 16 underwent RFA (inc 6 BTC pts), 3 CA during week 6 of tremelimumab therapy. 2 pts did not receive an ablative procedure. No DLT encountered. Most common toxicity was pruritus. One patient developed pulmonitis and was taken off study but remained disease-free at 16m. Of N = 17 pts evaluable for response outside of TACE/RFA-treated lesion 4 (23.5%) achieved confirmed partial responses. 8 of 9 pts with quantifiable HCV experienced a marked reduction in viral load. 6-week tumor biopsies showed immune cell infiltration on all evaluable patients. Median PFS for the evaluable HCC population (N = 25) was 5.7m. Conclusions: Tremelimumab in combination with subtotal TACE, RFA or CA in patients with advanced HCC and BTC is safe and feasible. Obtaining tumor biopsies at baseline and at the time of RFA/TACE is safe. Evidence of immune cell infiltration was seen on evaluable patients. Encouraging clinical activity seen with objective confirmed responses, PFS 5.7m and possibly surrogate reductions in HCV viral load. Clinical trial information: NCT01853618.

Sign in / Sign up

Export Citation Format

Share Document